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The role of the androgen receptor (AR) in male sexual dif-
ferentiation is revealed in part by the analysis of naturally
occurring mutations in families with androgen insensitivity
syndrome (AIS). We have investigated a family with partial
AIS affecting three generations and have identified a G to A









the A of the ATG initiation codon changing the second
amino acid residue from glutamic acid to lysine (EK2).
Transient expression of the mutant EK2-pCMVhAR ex-
pression vector in COS cells revealed decreased translation
with a 20–50% reduction in mutant protein relative to wild







































0.11 h). Cotransfection studies using an andro-
gen responsive luciferase reporter vector demonstrated a
50% reduction in transcriptional activation by EK2. These
functional alterations are consistent with the partial AIS
phenotype in affected males, corroborate the AR amino-ter-
minal domain effect on kinetics of androgen binding, and
provide physiological evidence for earlier translation exper-
iments identifying the nucleotide sequence for optimal
translation initiation. (
 
J. Clin. Invest. 
 
1996. 98:1423–1431.)

















 is a member of the steroid hor-
mone receptor superfamily of ligand dependent transcription
factors. AR interacts with specific DNA sequences known as
androgen response elements which occur adjacent to and
within responsive genes, resulting in hormone regulated tran-
scription (1). The receptor shares sequence similarity with
other steroid receptors within its three primary functional re-
gions: the amino-terminal, DNA binding, and steroid binding
domains. The amino-terminal domain, which constitutes 60%
of the AR coding sequence, is the least conserved and least
well defined of the three major domains and contains two
polymorphic sequences of glutamine and glycine repeats (2–5).
Analyses of AR deletion mutant constructs indicate that the
amino-terminal domain is essential for transactivation and is
inhibited by the steroid binding domain in the absence of an-
drogen. Recent evidence shows also that the extreme amino
terminus is important for receptor stabilization and steroid
binding (6). The DNA binding domain is the most highly con-
served region and interacts with androgen response elements
(1, 2, 7). The carboxyl-terminal region contains the steroid
binding domain, which inhibits transcriptional activation in the
absence of androgen, and binds androgen with high affinity re-
sulting in AR activation (7, 8).
In our investigation of the molecular basis for androgen re-
sistance in a family with partial AIS, grade III (9), we have
identified a G to A mutation that results in a glutamic acid to








 of the A in
the ATG initiation codon. In vitro translation experiments
have shown previously that a G in this position relative to the
ATG initiation codon affects the initiation of protein synthesis
(10). Here we report a novel mechanism of androgen resis-
tance, namely reduced AR protein expression resulting from
disruption of the nucleotide initiation sequence for protein
translation. Our investigations provide in vivo evidence sup-
porting the importance of the highly conserved sequence
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 AIS, androgen insensitivity syn-






Modified Eagle’s Medium; EMEM, Eagle’s minimal essential me-
dium; EK2, androgen receptor mutant expression vector, glutamic













gree is shown in Fig. 1. The index case II-1 (karyotype 46 XY) was as-
signed a female sex at birth. At 3 yr of age sex assignment was altered
to male. Ambiguous genitalia were characterized by perineal hypospa-
dias, microphallus and labioscrotal fusion, and a urogenital sinus. Testes
were present bilaterally in the inguinal canals. Two younger male sib-
lings, subjects II-4 and II-10, had similar phenotypes. A cystourethro-
gram and vaginogram performed at 9 yr of age in subject II-10 dem-
onstrated a short straight urethra extending into the bladder, absent
verumontanum, and a second opening posterior to the urethral me-
atus leading into a rudimentary vagina. Histology of testicular biop-
sies from subject II-10 showed narrow seminiferous tubules lined by
undifferentiated Sertoli cells and scanty germinal cells. On physical
examination at 20 yr of age, subject II-10 was 183-cm tall with a fe-
male body habitus, a broad pelvis, gynecomastia, Tanner stage 4 pubic
hair development, and absent facial hair. Genitals consisted of in-
guinal testes, perineoscrotal hypospadias at the apex of marked labio-





centile). The phenotype is consistent with partial AIS, grade III (9).










Gonadotropin levels (LH 2 U/liter and FSH 1 U/liter) were within the
laboratory reference range for adult males. A normal sevenfold rise in
LH levels was observed following stimulation with 100 U of LHRH.
Analysis of 0.2 ml sample of semen revealed azoospermia. Subject II-10
had prominent breast development which required reduction mastec-
tomies at 20 yr of age. Family members did not consent to genital skin
biopsy for analysis of fibroblast AR binding characteristics.
 
AR gene analysis. 
 
Genomic DNA was obtained from peripheral





 gene were amplified by PCR and exons 2–8 were screened
for single base mutations by denaturing gradient gel electrophoresis
(DGGE). All exons were subsequently subjected to direct sequence
analysis using methods described in detail elsewhere (12, 13). The nu-
cleotide mutation identified was confirmed in two separate sequenc-
ing reactions from two primary amplifications of genomic DNA from
subject II-1 and by direct sequencing of DNA from subjects II-4 and
II-10.
An allele specific PCR based protocol was developed to identify
carriers of the mutation as the glutamine polymorphic repeat was not









, contains a 2 base
substitution in its sequence (underlined) creating a BspH1 restriction
site when the EK2 mutation is present. After a 30 cycle PCR amplifi-










202-bp PCR product was digested with BspH1 (New England Bi-
olabs, Beverly, MA). A 171-bp fragment results when the mutant al-
lele is present; no digestion occurs when the normal allele is amplified
(see Fig. 3).
 
Construction of the hAR EK2 mutant cDNA expression plasmid
by site directed mutagenesis. 
 
The expression plasmid pCMVhAR
containing the hAR cDNA (4) was used to construct a mutant AR
cDNA containing the AR gene mutation identified in this family. Se-









 which contains Xba1 and Bgl2




 of the ATG initiator codon and the
antisense primer noted above which contains an Nar1 site were used
in PCR amplification of a 399-bp fragment of genomic DNA from
subject II-1. The PCR product and wild type expression vector were
digested with Nar1 and Bgl2 (GIBCO BRL, Gaithersburg, MD), pu-
rified by extraction from 0.5% agarose, and ligated at room tempera-
ture using T4 ligase (Promega Biotech, Madison, WI). Recombinant






 competent cells was se-
quenced to confirm the presence of the mutation and the absence of
other base changes. The recombinant plasmid pCMVhAR-EK2, des-
ignated EK2, contained an additional Xba1 site adjacent to the Bgl2
site enabling differentiation of the mutant EK2 clone from pCM-
VhAR.
 
Transient cotransfection assays of transcriptional activity. 
 
CV-1 cells
(American Type Tissue Culture Collection; Rockville, MD) were








 and cultured in Dul-
becco’s modified essential medium with high glucose (DMEM-H;
JRH Biosciences, Lenexa, KS) and 10% FCS (Irvine Scientific). Af-
ter 20 h, the cells were transfected with either 10 or 100 ng of pCM-




g of the mouse mammary
tumor virus promoter (MMTV luciferase) reporter vector (provided
by R.M. Evans, Salk Institute, La Jolla, CA) using the calcium phos-
phate precipitation method (14). 4 h after transfection the cells were
exposed to 15% glycerol for 4 min at room temperature and washed

















). After glycerol shock,
and again 20 h later, the medium was changed to serum-free, phenol-





Co., St. Louis, MO) at the concentrations indicated in Fig. 6. 48 h af-
ter transfection, cells were collected in 0.4 ml lysis buffer (Ligand
Pharmaceuticals). Luciferase activity was determined by analysis of
relative light units using a Monolight 2010 Analytical Luminescence
Laboratory luminometer. All experiments were performed in triplicate.
 
Assessment of AR expression and androgen binding kinetics.
 
For immunoblot analysis of AR protein, COS-1 cells (ATCC) were
transfected in duplicate with the indicated concentrations of AR ex-
pression vector (see Fig. 7) using the calcium phosphate precipitation








cells per 60 mm dish. After glycerol shock, cells were incubated in




l of 2% Na
dodecyl sulfate (SDS), 10% glycerol, and 10 mM Tris, pH 6.8. Immu-
noblot analysis of COS cell extracts for expressed AR was performed
using the polyclonal antibody AR 52 raised against an AR synthetic
peptide (amino acids 544–558) (15). Whole cell androgen binding and
intracellular androgen dissociation rates were determined in COS
cells transiently transfected with the mutant EK2 and wild type pCM-














Ci/mmol; DuPont New England Nuclear, Wilmington, DE) were
used in the assays. Protein content was determined by the method of
Lowry (16).
 
Analysis of AR translation efficiency and protein degradation
rates. 
 








 cells/10 cm dish




g AR expression vector DNA using DEAE
dextran. 24 h after transfection, DMEM-H containing 10% FCS was
replaced with serum free, phenol red-free medium. After a further 24 h,
cells were washed and incubated for 20 min in 4 ml methionine-free
Eagle’s minimal essential medium (EMEM; GIBCO BRL) contain-



























regular time intervals, the cells were placed on ice. Medium was aspi-
rated immediately, cells were washed once with PBS and harvested in
RIPA buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS, 0.15 M
NaCl, 5 mM EDTA, 50 mM Tris, pH 7.4). After passage through a
pasteur pipette to shear the DNA, the samples were centrifuged for




C. Cell extracts were immunoprecipitated as previously
described with the antibody AR 52 and analyzed on 9% acrylamide





(Millipore Corp., Bedford, MA), the filters exposed to x-ray film and
the AR bands quantitated by laser densitometric absorbance scan-
ning using a LKB Ultra scanner (Pharmacia Fine Chemicals, Piscat-




 version 2.1 (Pharmacia).
For determination of AR degradation rates, the protocol de-
scribed for determining efficiency of translation was modified such





Trans label for 30 min, washed with PBS and incubated for 2, 4, or 6 h
in medium containing 1 nM DHT. Cells were harvested in RIPA after
the specified time intervals of incubation and processed as described (6).
 
Northern blot analysis. 
 
Total RNA was extracted from trans-
fected COS cells by the acid guanidinium thiocyanate phenol method
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Figure 1. Family pedigree demonstrates X-linked inheritance of am-
biguous genitalia consistent with the partial androgen insensitivity 
syndrome. (j) Affected; (() carrier; (h/s) unaffected; (n) fetus of 
unknown sex. Subjects: I-3, II-1, II-4, II-10, and III-2 were 46 XY 
males born with ambiguous genitalia. Female sex of rearing was ini-
tially assigned to I-3, II-1, and III-2. This was reversed to male in mid-
dle childhood for I-3 and II-1. Subject III-2, reared as female, had a 
gonadectomy at 14 yr of age. Asterisk denotes female family mem-
bers screened for the EK2 mutation. The absence of the EK2 muta-















blot analysis of AR mRNA was performed as described (18) with mi-




g of total RNA was denatured with glyoxal









 DNA fragment extending
from nucleotide 2559 to 2894 of the cDNA sequence (4) was synthe-





















Arlington Heights, IL) by
random priming using Random Primed DNA labeling kit (Boeh-
ringer Mannheim, Mannheim, Germany) according to manufac-
turer’s instructions. Hybridization reactions were carried out over-
night in 0.75 M NaCl, 7.5 mM sodium citrate, pH 7.0, 5X Denhardts,









were washed to high stringency using 1.5 mM NaCl, 1.5 mM sodium

















C with intensifying screens. After
AR analysis, Northern blots were stripped by boiling in 0.5% SDS for





 (Ambion, Inc., Austin, TX) to standardize for RNA
loaded in each sample. Autoradiograms were analyzed by laser densi-




AR gene sequence. 
 
To determine the molecular basis of par-
tial AIS in this family, the coding region of the AR gene was
amplified from genomic DNA of subject II-1 by PCR. Agarose
gel electrophoresis of PCR products indicated that all eight ex-
ons were present. Screening by DGGE of exons 2–8 indicated
the absence of a base change in these exons. The region encod-
ing the amino-terminal domain within exon A was analyzed by
direct sequencing. A guanine (G) to adenine (A) base muta-




 of the A nucle-
otide of the ATG initiation codon. This mutation converted
the second codon from GAA to AAA and resulted in a
glutamic acid (E) to lysine (K) substitution at the extreme
amino terminus of AR (Fig. 2). Identical results were obtained
in subjects II-4 and II-10. The CAG glutamine repeat within
exon A numbered 21 residues in all 3 subjects. The polymor-
Figure 2. (A) Schematic representation of the single base mutation 
identified in exon 1 of the AR gene of three affected individuals with 
partial AIS. The G→A transition mutation at nucleotide position 14 
resulted in a glutamic acid to lysine substitution at amino acid residue 
2 (EK2) adjacent to the initiation methionine residue (shown above). 
The 21 Gln and 24 Gly repeat segments in these patients are depicted. 
The exons coding DNA and hormone binding domains (indicated) 
had normal nucleotide sequence. The amino acid codon numbers are 
indicated below. (B) Black and white reproduction of a color tracing 
of the nucleotide sequence analysis of the portion of the AR gene of 
affected subject XY II-1 showing the G→A mutation at position 14. 
A tracing of the wild type sequence AR gene is shown on the right. 
The four nucleotides are represented by broken and dashed lines. 
The nucleotides and their amino acid codons are indicated above 
their respective peaks. Asterisk indicates the alteration of G at 14 to 
A in the EK2 mutant sequence. (C) Consensus optimal sequence for 
protein translation initiation (2) where the A of the ATG codon is 







phic glycine repeat numbered 24 in II-1. The absence of a mu-
tation in exons 2–8 suggested by DGGE, was confirmed by di-
rect sequencing. Three heterozygote carriers of the mutant
EK2 allele (subjects I-2, II-3, and II-6) were identified by a
PCR based strategy using a mutagenic primer (Fig. 3), subjects
II-8 and III-6 who were potential carriers of the AR gene mu-
tation had only the normal allele.
 
Androgen binding of the mutant AR transiently expressed in
COS cells. 
 
To investigate the effect of the glutamic acid to
lysine substitution on AR function, the mutation was con-
structed in an expression plasmid containing the human AR
cDNA using PCR directed mutagenesis. Mutant and wild type
AR cDNAs were transiently expressed in COS cells and an-
drogen binding properties of expressed wild type and mutant









H]R1881 binding demonstrated similar equilib-


























































































 5 5) were slightly increased compared with
wild type AR (t1/2 5 2.460.11 h, n 5 5) (P , 0.001) (Fig. 5).
Transcriptional activity of EK2 AR. Transcriptional activ-
ity of EK2 mutant AR was assessed in CV1 cells cotransfected
with the reporter plasmid MMTV-luciferase. At the lower con-
centration of 10 ng transfected plasmid, EK2 induced 50% less
transcriptional activity in absolute optical units than wild type
receptor assayed in parallel under identical conditions (Fig. 6 A).
Induction of luciferase activity by EK2 was equal to or greater
Figure 3. Detection of the EK2 mutation in the AR gene of heterozy-
gote carriers in ethidium bromide stained 2% agarose gels containing 
PCR products. PCR amplification of a fragment encompassing the 
EK2 mutation was accomplished using a mutagenic primer. A BspHI 
site was created by the EK2 mutation, resulting in a single 171-bp 
fragment in affected 46 XY individuals on restriction enzyme diges-
tion, a single undigested 202-bp fragment in unaffected males and two 
bands in XX heterozygote carriers. (Top) Molecular weight markers 
(lane 1), undigested PCR product from subject XX II-3 (lane 2); after 
BspHI digestion: normal (202-bp) and mutant (171-bp) alleles are ap-
parent in genomic amplifications from subjects XX II-3 and XX II-6 
(lanes 3 and 4); only the normal (202-bp) allele in XX II-8 (lane 5). 
(Bottom) Molecular weight markers (lane 1); PCR products from two 
affected 46 XY males, XY II-1 and XY II-10 after digestion (lanes 2 
and 3); lane 4 shows undigested PCR product from subject XY II-10.
Figure 4. Androgen binding of the mutant AR EK2 recreated in 
vitro. Saturation plot (A) and Scatchard analysis (B) from a represen-
tative experiment of [3H]R1881 binding performed in duplicate in 
COS cells transfected with wild type (s) or EK2 (m) AR cDNA ex-
pression vectors. Equilibrium dissociation constants (Kd) were similar 
for the mutant EK2 (Kd 5 0.7060.14 [SE] nM, Bmax 5 0.5260.17 
pmol/mg protein, n 5 6) and wild type AR (Kd 5 0.6460.11 nM, 
Bmax 5 0.9660.43 pmol/mg protein, n 5 6).
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than that of wild type AR only when 100 ng of expression vec-
tor was transfected and incubated with greater than 0.1 nM
DHT (Fig. 6 A). However, fold induction of luciferase activity,
which represents the ratio of activity observed in cells treated
with steroid versus that in untreated cells transfected with the
same vector, was similar for EK2 and wild type at both concen-
trations of transfected DNA (Fig. 6 B).
Expression of the mutant AR. To test the hypothesis that
the efficiency of protein translation is reduced by the EK2 mu-
tation, AR protein in COS cells 48 h after transfection was de-
termined by immunoblot analysis using the AR 52 anti-pep-
tide antibody. The level of expression of EK2 AR protein was
50% lower than that of the wild type AR at 0.2 and 0.6 mg of
transfected expression vector. At the higher concentrations of
1 and 4 mg of transfected cDNA, EK2 levels were z 38 and
20%, respectively, lower than wild type AR. Reduced EK2 ex-
pression relative to wild type AR was observed in four sepa-
rate experiments when 0.2–1 mg of cDNA and in three out of
four experiments when 4 mg of cDNA expression vector was
transfected (Fig. 7).
To ascertain whether the lower level of mutant AR protein
expression resulted from differences in AR mRNA, Northern
analysis for AR mRNA (Fig. 8, A and B) was carried out using
COS cells transfected with 0.2–4 mg of expression plasmid
DNA cultured in parallel conditions as described above for
AR protein expression. No significant difference was observed
between EK2 mutant and wild type AR mRNA levels indicat-
ing that the reduced level of EK2 AR protein observed in COS
cells is not attributable to decreased mRNA expression or sta-
bility.
To investigate further the mechanism underlying reduced
expression of the mutant AR protein, the relative translation
efficiencies of EK2 and wild type AR mRNA were compared
by quantitation of [35S]methionine Trans-labeled AR protein
expressed in COS cells immediately after pulse labeling. At
the 5 and 10 min time points, the amount of EK2 AR protein
expressed was z 50% less than that of wild type AR (P 5 0.01,
n 5 5). At later time points up to 60 min after labeling, no sig-
nificant differences between mutant and wild type AR protein
expression were observed (P . 0.4) (Fig. 9).
In the absence of DHT the degradation rate of EK2 pro-
tein was not statistically different from that of wild type AR
(EK2 t1/2 5 1.460.1 [SE] h, wild type: t1/2 5 1.860.1 h, n 5 3)
(P 5 0.06). The rate of degradation of the EK2 and wild type
AR protein also did not differ in the presence of 1 nM DHT
(EK2: t1/2 5 2.760.5 [SE] h, wild type: t1/2 5 2.960.5 h, n 5 3).
Discussion
We have identified a novel missense mutation in the second
codon of the amino-terminal domain of the AR gene in three
related subjects with grade III partial AIS. The G→A substitu-
tion at nucleotide position 14 of the coding sequence resulted
in an amino acid change from glutamic acid to lysine and al-
tered the nucleotide context of the initiator codon. A survey of
the 59 ends of 699 vertebrate mRNA sequences has previously
demonstrated a conserved pattern of nucleotides surrounding
the functional initiator codon (19). The optimal context de-
rived from this survey was 59-CC CC UG -39 (19). Within
that sequence, the purine in position 23 on the 59 side of the
AUG is the most highly conserved, while 39 of the AUG
codon, G is the preferred flanking nucleotide, occurring in
46% of all mRNAs examined. In only 23 out of 699 was there a
pyrimidine at the 23 position and 17 of these contained a G at
the 14 position (19). Systematic mutagenesis of nucleotides
adjacent to the ATG initiator codon in preproinsulin expres-
sion confirmed the dominant effect of the purine in position 23
with a hierarchy of A . G . T in modulating the yield of pro-
tein (20). Alteration of G→T in the 14 position immediately
39 to the initiation codon was associated with a 50% reduction
in efficiency of translation; however, the effect of a G→A sub-
stitution in 14 was not determined (20). Nucleotide alterations
in positions 21, 22, 24, and 25 had no measurable effect
when the preproinsulin mutant contained the optimal A in po-
sition 23 and G in position 1 4 (20). The wild type human AR
mRNA sequence 59-CAAGGAUGG-39 contains A in the 23
position and G in position 1 4 but differs from the consensus
sequence at positions 21, 22, 24, and 25 (2).
We assessed the effect of the G→A EK2 mutation at posi-
tion 14 on AR protein expression using quantitative immuno-
blot analysis. The level of mutant AR protein expression was
reduced by z 20–50% compared with that of wild type AR
(Fig. 7) while mRNA levels were similar in COS cells trans-
fected with either EK2 or wild type AR (Fig. 8), thus the re-
duced level of EK2 AR protein observed in COS cells is not






Figure 5. Kinetics of androgen dissociation from wild type and mu-
tant EK2 AR. Wild type (s) and EK2 (m) expression vectors were 
transiently expressed in COS cells and incubated with 5 nM 
[3H]R1881. After a 2 h labeling period, dissociation was initiated by 
changing the media to contain a 10,000 fold excess of unlabeled 
R1881. Specific binding activity was determined as the difference in 
counts determined in the presence and absence of a 100-fold excess 
R1881 added at the beginning of the labeling period. The half time (t1/2) 
represents the time required for dissociation of half of the bound 
counts. A single representative dissociation curve of five experiments 
performed using transfected wild type and mutant AR is shown. For 
pCMVhAR, t1/2 5 2.460.11 [SE] h; for EK2, t1/2 5 1.760.08 h, n 5 5 
(P , 0.001).
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In translation experiments, the G→A substitution at 14
identified in the hAR from this AIS family reduces translation
of EK2 mutant AR protein. The amount of radiolabeled mu-
tant AR protein synthesized within the first 10 min was 50%
lower than that of wild type AR. This negative effect of the
EK2 mutation on translation likely results in lower steady state
mutant AR protein levels in vivo and leads to a severe partial
AIS phenotype. A precedent for such a mechanism is provided
by the report of a subject with a thalassemia (Haemoglobin H,
b-chain tetramers) in whom a deletion of the two nucleotides
preceding the ATG initiation codon which altered the se-
quence of the a globin gene from 59-ACCATG-39 to 59-CCC-
ATG-39 was associated with defective production of a-glo-
bin protein (21), even though levels of a globin mRNA in
reticulocytes were the same as in two unaffected subjects. The
authors of this study concluded that the defective output of a
chains most likely resulted from decreased efficiency of a glo-
bin mRNA translation. Our findings of equivalent AR mRNA
levels in COS cells transiently expressing wild type or EK2
mutant AR are consistent with the above observations that al-
teration of the optimal nucleotide context for translation initi-
ation can result in reduced protein synthesis. In unpublished
Figure 6. Transcriptional activa-
tion of an androgen responsive 
reporter gene by wild type and 
EK2 AR. (A) CV1 cells were 
transiently transfected with plas-
mids encoding either wild type 
or EK2 AR with expression vec-
tor DNA at 10 or 100 ng and the 
reporter plasmid MMTV-luci-
ferase (5 mg). After transfection, 
cells were incubated with in-
creasing concentrations of DHT 
for 48 h, harvested, and assayed 
for luciferase activity. The fig-
ure displays a representative ex-
periment showing a dose depen-
dent increase in transcriptional 
activity of both the wild type and 
EK2 mutant AR induced by 
DHT in absolute light units. 
Bars represent the mean of 
triplicates6SE. (B) Transcrip-
tional activity is plotted as fold 
induction which represents the 
ratio of luciferase activity in 
DHT treated cells to that in un-
treated cells transfected with the 
respective vector. The average 
from five independent experi-
ments is shown.
Androgen Receptor Amino-terminal Mutation Causes Reduced Protein Translation 1429
studies, we have observed in another family the phenotype of
partial AIS associated with reduced expression of a function-
ally normal AR supporting the requirement for AR expression
at a critical threshold level.
In keeping with the normal ligand binding domain se-
quence of the EK2 mutant, the equilibrium affinity binding con-
stant for [3H]R1881 was normal. However, normal kinetics of
androgen binding require an interaction between the AR amino
terminus and the ligand binding domain. The increased disso-
ciation rate of bound [3H]R1881 from the EK2 mutant is con-
sistent with but less marked than that observed in AR amino-
terminal deletion mutants (6). The naturally occurring ligand
binding domain mutation VM889 (22) which resulted in ten-
fold increased rate of ligand dissociation, was also associated
with enhanced AR degradation (6). The small apparent in-
crease in the degradation rate of EK2 noted in the absence of
DHT did not reach significance (P 5 0.06). Accordingly the rate
of receptor degradation was similar for EK2 and wild type AR
in the presence of DHT. However small increases in dissocia-
tion of bound androgen and AR degradation resulting from al-
Figure 7. Immunoblot quantitation of AR protein. COS cells were 
transfected in duplicate with increasing amounts of AR mutant or 
wild type expression vector cDNA, incubated in Dulbecco’s modified 
medium, pH 7.2, supplemented with 10% fetal calf serum, 20 mM 
Hepes, pH 7.2, and antibiotics in humidified 5% CO2 and harvested 
at 48 h. Immunoblot analysis was performed using the rabbit anti AR 
polyclonal antibody AR 52 and a fluorescein tagged goat anti–rabbit 
IgG antibody. (A) A representative blot of COS cell extracts after 
transfection with 4–0.2 mg per plate of wild type AR cDNA vector 
(lanes 1–4) and with EK2 cDNA (lanes 5–8). Lane 9 contains full 
length AR derived from baculovirus infected Sf9 cells (33). The up-
per band is the full length AR protein. Each lane represents an equal 
volume of extract obtained from a plate of 400,000 cells. (B) Densito-
metric analysis of three immunoblots prepared as described above. 
The bars represent the mean6SE of AR protein levels expressed in 
densitometric units at each concentration of AR DNA transfected 
and indicates that transient EK2 expression (hatched bars) deviates 
from wild type (solid bars) by 50% at lower concentrations and 38 
and 20% at the higher concentrations of 1 and 4 mg, respectively.
Figure 8. Northern blot of AR mRNA in transfected COS cells. AR 
mRNA was isolated from 4.5 3 105 COS cells 48 h after calcium phos-
phate transfection of indicated amounts of DNA performed as de-
scribed for immunoblot analysis of AR. Aliquots of total RNA (10 
mg) were analyzed by blot hybridization using an AR DNA probe as 
described in Methods. (A) A representative blot is shown of RNA ex-
tracted from COS cells after transfection with 4 mg per plate of con-
trol parent vector pCMV5 (34) (lane 1), 0.2–4 mg wild type AR 
cDNA (lanes 2–5) and mutant EK2 AR cDNA vector (lanes 6–9). 
(Top) Hybridization with AR cDNA probe. (Bottom) The blot was 
stripped and hybridized with 18S rRNA cDNA probe to control for 
RNA loading. (B) The radioactive bands on autoradiographs were 
quantified by laser densitometry for AR and 18S rRNA. The data 
points representing the mean of four transfections6SE of AR RNA 
expressed in transfected COS cells and standardized against 18S 
RNA are plotted in densitometric units versus the amount of DNA 
transfected per plate.
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teration of the normal amino and carboxy-terminal interaction
within the mutant EK2 AR could exacerbate reduced AR pro-
tein levels and thereby contribute to the phenotype of partial AIS.
The reduced AR transactivation of the MMTV-luciferase
reporter gene by the EK2 mutant compared with wild type
AR, at 10 ng of transfected expression vector is consistent with
the reduction of EK2 AR protein expression at the lower level
of transfected DNA. When 100 ng of transfected cDNA was
used in the presence of $ 0.1 nM DHT, transcriptional capac-
ity of the EK2 mutant approached wild type levels. Thus the
higher concentration of steroid compensated for the effect of
the EK2 mutation at higher levels of protein expression. How-
ever the fold induction achieved with steroid treatment was
similar for EK2 and wild type AR at 10 and 100 ng suggesting
that the inherent transcriptional capacity of the receptor was
similar to wild type AR. The predominant effect of the EK2
mutation is therefore to decrease protein translation.
Intermolecular interactions with the human AR dimer
have previously been investigated using a protein interaction
assay in which the amino terminus and the carboxyl terminus
were fused to the Saccharomyces cervisiae GAL4 DNA bind-
ing domain and the herpes simplex virus VP-16 transactivation
domain in order to produce chimeric proteins (23). Amino-ter-
minal deletion chimeras in this assay demonstrated that the re-
gion near the amino-terminal end contributes to receptor
dimerization following high affinity ligand binding. However,
this effect was not as strong as that for the amino-terminal re-
gion adjacent to the DNA binding domain (23). The single
amino acid alteration at position two does not appear to have a
substantial effect on receptor dimerization, as indicated by our
findings of normal transcriptional activity of the EK2 mutant
at higher levels of receptor expression.
With few exceptions, mutations in the human AR gene as-
sociated with AIS have been limited to the DNA and steroid
binding domains (9, 24–27). Types of amino-terminal domain
mutations include premature stop codons (28), frameshifts (29,
30) and a single missense mutation, (31) and expansions of the
homopolymeric CAG trinucleotide repeat (32). In the present
report, we characterize a novel molecular mechanism for AIS
resulting from a G to A substitution in codon 2 adjacent to the
translation initiation codon in the amino-terminal domain of
the AR in three related individuals with partial AIS. This is the
first report of a naturally occurring mutation that alters the nu-
cleotide context of the ATG initiation codon at the critical G
14 residue, resulting in reduced translation efficiency.
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